Vaccine production us11/12/2023 ![]() ![]() Many biotechnological companies and partnerships are involved, collaborating and competing against each other to develop and produce effective and safe vaccines. Given how sensitive the issue of equitable vaccine distribution has become, it is almost certain that foreign and international economic policy goals of the Biden Administration will be compromised if this matter is handled poorly.There are over a hundred vaccines against SARS-CoV-2 in development, including at least 54 vaccines currently being tested on human subjects. The optics of the United States sitting on 0.5 to 1 billion surplus vaccine doses later this year will color the perceptions of the Biden administration. Done right, the United States could be in the vanguard of global vaccine distribution from the third quarter of this year. Recent months have shown that even with international trade restrictions, these variants cross borders and threaten lives. Variants are springing up where large fractions of foreign populations remain unvaccinated. public health will be safeguarded by distributing surplus vaccines. ![]() can contribute to vaccine dissemination outside of North America is materially affected by the scenario chosen. vaccine reserve created the later surpluses become available (see scenarios 3a, 3b, and 3c below). ![]() Should the White House decide to inoculate the populations of Canada and Mexico as well as every American aged 5 and over, then a surplus becomes available by September 16. vaccine surplus is estimated to be over 1 billion doses. Even with the latter approach, by the end of the year, the U.S. These two dates move back to July 18 and October 18, respectively, if American children are inoculated as well. Following that, a surplus of 500 million doses will have accumulated by September 25. adult population should be completed by June 20, 2021. ![]() Production necessary to vaccinate the U.S. vaccine production facility, we report the date when the required production level is met (see column 4) and the dates when any surplus generated thereafter reaches 100 million, 500 million, and 1 billion doses. Using detailed data on production schedules per U.S. Vaccinate the populations of Canada and Mexico as well.Įach objective requires a certain amount of vaccine doses to be produced (see column 3).Create vaccine reserves (three options are presented each with a different scale).We defined four scenarios, each reflecting different possible U.S. Third, vaccination rates in Canada and Mexico lag behind those in the United States. Second, fears have been expressed about future variants and the need to build up a U.S. First, some vaccines have reported high levels of efficacy among children, raising the question as to whether inoculation will be extended to Americans aged 5 years or older. Recently, Matt Linley and I worked through a series of scenarios based on the following recent developments. takes concerning its own vaccine rollout, the reserves it decides to build, and the policy toward its neighbors. But just how much surplus vaccine will the U.S. India, a potential ally in geopolitical rivalry with China, is mentioned as a potential beneficiary, not least given the surge in COVID-19 infections there. Last week, the administration went further and announced that up to 60 million doses of the AstraZeneca vaccine would be available to other countries. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |